Mangalam Drugs & Organics Surges 5% After Kedia’s Bulk Deal

Mangalam Drugs & Organics Ltd, a micro-cap pharmaceutical company, witnessed a strong rally after a strategic purchase by ace investor Vijay Kedia. On December 29, 2025, Kedia bought 1,37,794 equity shares through a bulk deal worth approximately ₹33.27 lakh at ₹24.15 per share, a 1.5% premium over the previous closing price. This purchase was made via Kedia Securities Private Ltd, the investment vehicle of Vijay Kedia, reflecting confidence in the long-term prospects of Mangalam Drugs despite its recent underperformance.

Following Kedia’s stake acquisition, Mangalam Drugs’ stock surged around 5% during intraday trading, closing at ₹24.96 and hitting the upper circuit, the maximum permissible daily rise, indicating strong buying pressure. Intraday price movement ranged from ₹22.80 to ₹24.96, and total traded volume was approximately 2.19 lakh shares with a turnover of ₹0.52 crore. The lower delivery volume, down ~15% from the recent average, suggests many trades were short-term or speculative, highlighting the volatile nature of micro-cap stocks.

Mangalam Drugs, headquartered in Vapi, Gujarat, manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, including anti-malaria APIs. The company operates multiple manufacturing facilities and an in-house R&D lab recognized by the Department of Scientific & Industrial Research (DSIR), Delhi. Despite its established operations, the company recently faced financial challenges, reporting a consolidated net loss of ₹7.4 crore, compared with a net profit of ₹2.7 crore in the prior year. Revenue fell 38% to ₹50 crore from ₹80 crore in the corresponding previous quarter.

The stock has exhibited high volatility over the past year, trading nearly 80% below its 52-week high of ₹124.89 and hovering just above its 52-week low of ₹22.80 before Kedia’s purchase. Its micro-cap status, market capitalization of ~₹37–39 crore, and sector focus on Pharmaceuticals & Biotechnology contribute to its high-risk, high-reward profile. On December 29, the broader Pharmaceuticals & Biotechnology sector declined ~0.47%, while Sensex fell ~0.40%, showing that Mangalam Drugs’ rally was independent of broader market trends.

Technical indicators show the stock trading above its 5-day moving average, providing short-term support, but still below its 20-, 50-, 100-, and 200-day averages, signaling medium- and long-term weakness.

Vijay Kedia’s bulk deal is seen as a bullish signal from a respected investor, often attracting retail investor attention and short-term price momentum in small-cap or micro-cap stocks. This type of insider buying can act as a catalyst for upward movement even amid weak fundamentals, as seen with the upper circuit hit.

In summary, Mangalam Drugs & Organics Ltd surged to its upper circuit limit on December 29, 2025, following Vijay Kedia’s strategic share purchase. The rally reflects short-term buying interest and market confidence in the long-term value potential of the micro-cap pharmaceutical company, despite ongoing financial and operational challenges.